Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep681 | Pituitary and Neuroendocrinology | ECE2023

Prediction of the receptor phenotype of somatotrophic tumors and the effectiveness of the use of the first-generation somatostatin receptor ligands (fg-SRLs) in the long-term treatment of acromegaly

Pronin Evgeny , Antsiferov Mikhail , Alekseeva Tatiana , Lapshina Anastasia , Pronin Vyacheslav

The control of acromegaly with drug therapy (DT) by fg-SRLs is achieved only in 40–50% of cases, due to the heterogeneous composition of somatotrophic tumors. In order to optimize DT stratification of clinical and immunophenotypic biomarkers which make it possible to predict the long-term effectiveness of fg-SRLs at early stages is required. The aim of the work was to assess the informativeness of pharmacotherapeutic testing (% of decrease of IGF-1 level after 3 and 6 mon...

ea0032p872 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Ursodeoxycholic acid role in chronic cholecystitis progression prevention in acromegaly patients receiving somatostatin analogues

Poteshkin Yuriy , Pronin Vyacheslav , Pronin Evgeny , Kotlyarevskaya Evgenia , Morozova Maria

Introduction: Acromegaly – a serious debilitating disease resulting in decreased quality and length of life. Due to the late nature of the diagnosis, the lack of prospects for a surgical or non-radical adenomectomy leads to a somatostatin analogues (SA) treatment as primary or secondary therapy, which is a long-term, sometimes lifelong. Therefore, the question of tolerability and prevention of life-threatening complications for these patients is very important. Since the ...